The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome

Koblik, Teresa; Sieradzki, Jacek; Sendur, R; Biernat, Jolanta; Czarnobilski, K; Gryz, Elzbieta A; Pawlik, W; Szczudlik, Andrzej; Gaddi, Antonio Vittorino

doi:10.1016/s1056-8727(00)00134-3

Cited by 17 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The drug is absorbed orally8,31 and although it was first evaluated as an anti-thrombotic drug, it has no anticoagulant effect after oral administration 32. The drug has been shown to improve blood flow by lowering viscosity,33,34 to reduce the occurrence of cardiovascular events and to improve vascular disease-associated skin ulcers 35-37…”

Section: Discussionmentioning

confidence: 99%

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

et al. 2011

View full text Add to dashboard Cite

PurposeWe conducted a multi-center randomized double-blind study to determine the effects of 6-month therapy with sulodexide on urinary protein excretion in patients with idiopathic Immunoglobulin A (IgA) nephropathy.Materials and MethodsA total of seventy-seven patients participated in the study. They were randomly allocated to one of three groups: sulodexide 75 mg or 150 mg daily or the placebo for 6 months. The primary end point was the achievement, at 6 months, of at least 50% reduction in urine protein/creatinine ratio (UPCR) from the baseline value.ResultsAt 6 months, the primary end point was achieved by 12.5% of the patients assigned to the placebo, 4.0% of the patients assigned to sulodexide 75 mg daily and 21.4% of those assigned to 150 mg (p=0.308). Treatment with sulodexide 150 mg daily for 6 months significantly reduced log UPCR from 6.38±0.77 at baseline to 5.98±0.94 at 6 months (p=0.045), while treatment with sulodexide 75 mg daily and placebo did not.ConclusionA 6-month treatment with sulodexide did not achieve 50% reduction of urinary protein excretion in IgA nephropathy patients, but showed a tendency to increase the time-dependent anti-proteinuric effect. Therefore, long-term clinical trials on a larger scale are warranted to elucidate the hypothesis that sulodexide affords renal protection in IgA nephropathy patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Furthermore, sulodexide has other pharmacological effects potentially useful in the diabetic patients, subject to a high probability of developing acute cardiovascular diseases: anti-thrombotic activity, decrease of oxidative stress, hypolipidemic effect, prevention of glucose toxicity, suppression of cellular inflammation and anti-atheromatous effects [6]. Several clinical studies demonstrated sulodexide efficacy in patients, diabetic and not diabetic, affected by vascular diseases associated with a thrombotic risk: peripheral occlusive arterial diseases [29,30], prevention of recurrent deep venous thrombosis [31,32], diabetic retinopathy [33], diabetic foot [34,35], cerebrovascular [36,37] and cardiovascular diseases [38,39] and management of chronic venous disease, including the more severe and complicated cases such as venous ulcers [40][41][42].…”

Section: Discussionmentioning

confidence: 99%

A Clinical Experience on Sulodexide in the Treatment of Patients with Diabetic Nephropathy

Dakhli¹,

Khedher²,

Zidi³

et al. 2017

J Nephrol Ther

View full text Add to dashboard Cite

show abstract

“…Although it was first evaluated as an anti-thrombotic drug it has no anticoagulant effect after oral administration [27]. The drug has been shown to improve blood flow by lowering viscosity [28,29], to reduce cardiovascular events and to improve vascular disease-associated skin ulcers [30][31][32]. Gambaro first observed a relation between GAG and diabetic proteinuria in animal models and the suggested use of sulodexide in the treatment of diabetic nephropathy.…”

Section: Discussionmentioning

confidence: 99%

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

Heerspink

Greene

Lewis

et al. 2008

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background. Urinary albumin excretion frequently persists in diabetic patients who are treated with angiotensinconverting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). Sulodexide, a glycosaminoglycan mixture of 80% heparan sulfate and 20% dermatan sulfate, has been hypothesized to reduce persistent albuminuria. We have conducted a multi-center randomized double-blind pilot study in order to determine the effect of 6 months' therapy with sulodexide on urinary albumin excretion and to address logistical issues for a full-scale trial. Methods. A total of 149 patients with type 2 diabetes and an albumin:creatinine ratio (ACR) between 20 and 300 mg/g were randomized with equal allocation to either placebo, 200 mg of sulodexide or 400 mg of sulodexide. The primary endpoint was the achievement, at 6 months, of either 3(1) return to normoalbuminuria (ACR < 20 mg/g with a decrease of at least 25%) or (2) a decrease in ACR of at least 50% from the baseline value. All patients used a maximum tolerated recommended FDA approved dose of an ACEI or ARB for at least 60 days and had stable blood pressure prior to randomization. Results. The primary efficacy endpoint was achieved in 25.3% of the patients in the two sulodexide groups combined versus 15.4% of the placebo-treated patients (P = 0.26). The primary endpoint was achieved in 33.3% (P = 0.075 for the comparison to placebo) in the sulodexide 200 mg group and 18.4% (P = 0.781) in the sulodexide 400 mg group. (No consistent patterns of side effects were observed.Correspondence and offprint requests to: H. J. Lambers Heerspink, Department of Clinical Pharmacology University Medical Center Groningen, University of Groningen, A. Deusinglaan, 19713 AV Groningen, The Netherlands. Tel: +31-50-363-2809; Fax: +31-50-363-2812; E-mail: H.J.Lambers.Heerspink@med.umcg.nl Conclusion. Based on the experience gained in this pilot study, one full-scale trial is currently being conducted to evaluate the effects of sulodexide on change in ACR in patients with persistent microalbuminuria, and a longerterm trial is underway to evaluate the effects of sulodexide on long-term renal disease progression in patients with overt proteinuria.

show abstract

The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome

Cited by 17 publications

References 24 publications

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

A Clinical Experience on Sulodexide in the Treatment of Patients with Diabetic Nephropathy

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

Contact Info

Product

Resources

About